Business Update7 Jan 2026, 06:41 pm
Panacea Biotec Completes Enrolment for DengiAll Phase-III Clinical Trial
AI Summary
Panacea Biotec Ltd has completed the enrolment of study participants for the Phase-III clinical trial of its tetravalent dengue candidate vaccine, DengiAll®. This follows the initiation of the trial announced in August 2024. The company will monitor each participant for two years to examine the efficacy and immunogenicity of the vaccine. DengiAll®, expected to enter the markets by 2027, will be the first indigenous single-shot dengue vaccine in India.
Key Highlights
- Panacea Biotec completes enrolment for DengiAll Phase-III clinical trial
- 10,335 study participants enrolled
- Company to monitor participants for two years
- DengiAll® expected to be the first indigenous single-shot dengue vaccine in India
- DengiAll® expected to enter the markets by 2027